Dyne Therapeutics, Inc. Proceeds from Sale and Maturity of Marketable Securities
Dyne Therapeutics, Inc. (DYN) reported Proceeds from Sale and Maturity of Marketable Securities of $43.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-07-29
- Dyne Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $14.77M, a 168.72% increase year-over-year.
- Dyne Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $28.65M, a 864.58% increase year-over-year.
- Dyne Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $9.38M, a 6.44% increase year-over-year.
- Dyne Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $1.00K, a 99.94% decline year-over-year.
- Dyne Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2025 was $17.85M, a 69.00% increase from fiscal 2024.
- Dyne Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2024 was $10.56M, a 477.53% increase from fiscal 2023.
- Dyne Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $1.83M, a 42.01% decline from fiscal 2022.
- Dyne Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $3.15M, a 28.92% decline from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $43.42M 10-Q · filed 2026-07-29 | $52.80M derived: sum of 3 quarters · filed 2026-07-29 | $52.80M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $28.65M 10-Q · filed 2026-05-11 | $38.03M derived: sum of 2 quarters · filed 2026-05-11 | $38.03M derived: sum of 3 quarters · filed 2026-05-11 | $43.53M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $9.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.38M derived: sum of 2 quarters · filed 2026-03-02 | $14.88M derived: sum of 3 quarters · filed 2026-07-29 | $17.85M 10-K · filed 2026-03-02 |
| 2025-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.50M derived: sum of 2 quarters · filed 2026-07-29 | $8.47M 10-Q · filed 2025-11-05 | $17.28M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $5.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $8.47M 10-Q · filed 2026-07-29 | $17.28M derived: sum of 3 quarters · filed 2026-07-29 | $19.03M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $2.97M 10-Q · filed 2026-05-11 | $11.78M derived: sum of 2 quarters · filed 2026-05-11 | $13.53M derived: sum of 3 quarters · filed 2026-05-11 | $13.53M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $8.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $10.56M derived: sum of 2 quarters · filed 2026-03-02 | $10.56M derived: sum of 3 quarters · filed 2026-03-02 | $10.56M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.75M derived: sum of 2 quarters · filed 2025-11-05 | $1.75M 10-Q · filed 2025-11-05 | $1.75M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | $0.00 10-Q · filed 2025-07-28 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $0.00 derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-02 | $0.00 derived: sum of 3 quarters · filed 2026-03-02 | $1.83M 10-K · filed 2026-03-02 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $1.83M 10-Q · filed 2024-11-12 | $2.22M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.83M 10-Q · filed 2024-08-12 | $2.22M derived: sum of 3 quarters · filed 2025-02-27 | $2.22M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.83M 10-Q · filed 2024-05-02 | $2.22M derived: sum of 2 quarters · filed 2025-02-27 | $2.22M derived: sum of 3 quarters · filed 2025-02-27 | $2.47M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $395.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $395.00K derived: sum of 2 quarters · filed 2025-02-27 | $639.00K derived: sum of 3 quarters · filed 2025-02-27 | $3.15M 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | $244.00K derived: sum of 2 quarters · filed 2023-10-30 | $2.76M 10-Q · filed 2023-10-30 | $7.20M derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | $244.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.76M 10-Q · filed 2023-08-03 | $7.20M derived: sum of 3 quarters · filed 2023-08-03 | $7.20M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $2.52M 10-Q · filed 2023-05-11 | $6.95M derived: sum of 2 quarters · filed 2023-05-11 | $6.95M derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $4.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $4.44M derived: sum of 2 quarters · filed 2023-03-02 | $4.44M 10-K · filed 2023-03-02 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |